Related Experiment Video
Updated: Jun 30, 2026
13:01
Industrialized, Artificial Intelligence-guided Laser Microdissection for Microscaled Proteomic Analysis of the Tumor Microenvironment
Published on: June 3, 2022
Tissue proteomics for cancer biomarker development: laser microdissection and 2D-DIGE
1Proteome Bioinformatics Project, National Cancer Center Research Institute, Tokyo, Japan. takondo@ncc.go.jp
BMB Reports
|October 1, 2008
Summary
Identifying novel cancer biomarkers from tumor proteomes is crucial for early diagnosis and personalized therapy. Proteomic signatures in tumor tissues can reveal specific proteins for use as cancer biomarkers.
Area of Science:
- Proteomics
- Cancer Biology
- Biomarker Discovery
Background:
- Novel cancer biomarkers are essential for early diagnosis and tailored treatments.
- Tumor tissues offer a rich source of proteomic information for biomarker identification.
- Proteins released from tumors may serve as more specific plasma biomarkers.
Purpose of the Study:
- To investigate tumor tissue proteomes for identifying potential cancer biomarkers.
- To explore the utility of laser-microdissection and advanced proteomics for biomarker discovery.
- To emphasize the need for collaboration in translating biomarker research into clinical applications.
Main Methods:
- Utilizing laser-microdissection for precise isolation of tumor cells.
- Employing two-dimensional difference gel electrophoresis (2D-DIGE) with sensitive fluorescent dyes for protein expression profiling.
- Analyzing proteomic signatures correlated with clinico-pathological parameters.
Main Results:
- Proteomic signatures within tumor tissues can be identified.
- Specific proteins within these signatures show potential as cancer biomarker candidates.
- Laser-microdissection enables accurate proteomic profiling of specific cellular components.
Conclusions:
- Proteomics of tumor tissues, particularly with laser-microdissection and 2D-DIGE, is a viable strategy for novel cancer biomarker discovery.
- Identified protein biomarkers hold promise for improving early cancer diagnosis and therapy.
- Urgent collaboration is needed to translate proteomic findings into clinical applications for patient benefit.
